Alkermes has taken another step toward the market with its long-acting version of the schizophrenia drug Abilify, filing for an approval with the FDA as it lays the foundation for a hoped-for launch in 2015.

…read more

Source: Alkermes closer to launching once-monthly schizophrenia drug into a crowded market


0 No comments